<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:26:29Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:5902553" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:5902553</identifier>
        <datestamp>2018-04-20</datestamp>
        <setSpec>ncomms</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Nat Commun</journal-id>
              <journal-id journal-id-type="iso-abbrev">Nat Commun</journal-id>
              <journal-title-group>
                <journal-title>Nature Communications</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2041-1723</issn>
              <publisher>
                <publisher-name>Nature Publishing Group UK</publisher-name>
                <publisher-loc>London</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC5902553</article-id>
              <article-id pub-id-type="pmcid">PMC5902553</article-id>
              <article-id pub-id-type="pmc-uid">5902553</article-id>
              <article-id pub-id-type="pmid">29662077</article-id>
              <article-id pub-id-type="publisher-id">3905</article-id>
              <article-id pub-id-type="doi">10.1038/s41467-018-03905-6</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Article</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Pharmacodynamics of mutant-<italic>IDH1</italic> inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Andronesi</surname>
                    <given-names>Ovidiu C.</given-names>
                  </name>
                  <address>
                    <email>oandronesi@mgh.harvard.edu</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Arrillaga-Romany</surname>
                    <given-names>Isabel C.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ly</surname>
                    <given-names>K. Ina</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bogner</surname>
                    <given-names>Wolfgang</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ratai</surname>
                    <given-names>Eva M.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Reitz</surname>
                    <given-names>Kara</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Iafrate</surname>
                    <given-names>A. John</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff5">5</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Dietrich</surname>
                    <given-names>Jorg</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gerstner</surname>
                    <given-names>Elizabeth R.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Chi</surname>
                    <given-names>Andrew S.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff6">6</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Rosen</surname>
                    <given-names>Bruce R.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wen</surname>
                    <given-names>Patrick Y.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff7">7</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Cahill</surname>
                    <given-names>Daniel P.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Batchelor</surname>
                    <given-names>Tracy T.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">000000041936754X</institution-id><institution-id institution-id-type="GRID">grid.38142.3c</institution-id><institution>Department of Radiology, Massachusetts General Hospital, Athinoula A. Martinos Center for Biomedical Imaging, </institution><institution>Harvard Medical School, </institution></institution-wrap>Boston, MA 02129 USA </aff>
                <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">000000041936754X</institution-id><institution-id institution-id-type="GRID">grid.38142.3c</institution-id><institution>Department of Neurology, Massachusetts General Hospital, Stephen E. and Catherine Pappas Center for Neuro-Oncology, Division of Hematology/Oncology, </institution><institution>Harvard Medical School, </institution></institution-wrap>Boston, MA 02114 USA </aff>
                <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9259 8492</institution-id><institution-id institution-id-type="GRID">grid.22937.3d</institution-id><institution>Department of Biomedical Imaging and Image-guided Therapy, High Field MR Centre, </institution><institution>Medical University of Vienna, </institution></institution-wrap>Vienna, 1090 Austria </aff>
                <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">000000041936754X</institution-id><institution-id institution-id-type="GRID">grid.38142.3c</institution-id><institution>Department of Neurosurgery, Massachusetts General Hospital, </institution><institution>Harvard Medical School, </institution></institution-wrap>Boston, MA 02114 USA </aff>
                <aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">000000041936754X</institution-id><institution-id institution-id-type="GRID">grid.38142.3c</institution-id><institution>Department of Pathology, Massachusetts General Hospital, Center for Integrated Diagnostics, </institution><institution>Harvard Medical School, </institution></institution-wrap>Boston, MA 02114 USA </aff>
                <aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2109 4251</institution-id><institution-id institution-id-type="GRID">grid.240324.3</institution-id><institution>Brain Tumor Center, Laura and Isaac Perlmutter Cancer Center, </institution><institution>New York University Langone Medical Center and School of Medicine, </institution></institution-wrap>New York, NY 10016 USA </aff>
                <aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2106 9910</institution-id><institution-id institution-id-type="GRID">grid.65499.37</institution-id><institution>Dana-Farber Cancer Institute, </institution></institution-wrap>Boston, MA 02284 USA </aff>
              </contrib-group>
              <pub-date pub-type="epub">
                <day>16</day>
                <month>4</month>
                <year>2018</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>16</day>
                <month>4</month>
                <year>2018</year>
              </pub-date>
              <pub-date pub-type="collection">
                <year>2018</year>
              </pub-date>
              <volume>9</volume>
              <elocation-id>1474</elocation-id>
              <history>
                <date date-type="received">
                  <day>8</day>
                  <month>7</month>
                  <year>2017</year>
                </date>
                <date date-type="accepted">
                  <day>21</day>
                  <month>3</month>
                  <year>2018</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© The Author(s) 2018</copyright-statement>
                <license license-type="OpenAccess">
                  <license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p>
                </license>
              </permissions>
              <abstract id="Abs1">
                <p id="Par1">Inhibitors of the mutant isocitrate dehydrogenase 1 (<italic>IDH1</italic>) entered recently in clinical trials for glioma treatment. Mutant <italic>IDH1</italic> produces high levels of 2-hydroxyglurate (2HG), thought to initiate oncogenesis through epigenetic modifications of gene expression. In this study, we show the initial evidence of the pharmacodynamics of a new mutant <italic>IDH1</italic> inhibitor in glioma patients, using non-invasive 3D MR spectroscopic imaging of 2HG. Our results from a Phase 1 clinical trial indicate a rapid decrease of 2HG levels by 70% (CI 13%, <italic>P</italic> = 0.019) after 1 week of treatment. Importantly, inhibition of mutant <italic>IDH1</italic> may lead to the reprogramming of tumor metabolism, suggested by simultaneous changes in glutathione, glutamine, glutamate, and lactate. An inverse correlation between metabolic changes and diffusion MRI indicates an effect on the tumor-cell density. We demonstrate a feasible radiopharmacodynamics approach to support the rapid clinical translation of rationally designed drugs targeting <italic>IDH1/2</italic> mutations for personalized and precision medicine of glioma patients.</p>
              </abstract>
              <abstract id="Abs2" abstract-type="web-summary">
                <p id="Par2">Inhibitors of mutant isocitrate dehydrogenase 1 (IDH1) entered recently clinical trials for treatment of gliomas. Here, the authors apply a MRS imaging method for 2HG detection and assessement of the pharmacodynamic effects of the mutant IDH1 inhibitor (IDH305) in 8 mutant IDH1 glioma patients.</p>
              </abstract>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>issue-copyright-statement</meta-name>
                  <meta-value>© The Author(s) 2018</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec id="Sec1" sec-type="introduction">
              <title>Introduction</title>
              <p id="Par3">Recurrent heterozygous mutations in the isocitrate dehydrogenase 1 (<italic>IDH1</italic>) enzyme are very common in grade II-III glioma and secondary glioblastoma<sup><xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR2">2</xref></sup>, which now are recognized in the 2016 World Health Organization classification of central nervous system tumors<sup><xref ref-type="bibr" rid="CR3">3</xref></sup> to be a particular subtype of glioma characterized by the distinct molecular and clinical phenotypes. The metabolic hallmark of this glioma subtype is de novo production of high levels of the oncometabolite 2-hydroxyglutarate (2HG), exclusively in the form of the D-enantiomer (D-2HG), by the mutant <italic>IDH1</italic> enzyme through the NADPH-dependent reduction of α-ketoglutarate (αKG)<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>. <italic>IDH1</italic> mutation is an early genetic event in gliomagenesis, and 2HG is believed to further promote tumorigenesis through the inhibition of αKG-dependent dioxygenases<sup><xref ref-type="bibr" rid="CR5">5</xref></sup> and chromatin modifiers, resulting in DNA-/histone-hypermethylation and loss of the epigenetic control of gene expression<sup><xref ref-type="bibr" rid="CR6">6</xref>–<xref ref-type="bibr" rid="CR10">10</xref></sup>.</p>
              <p id="Par4">Gliomas are rarely curable tumors with a low survival rate (34%) at 5 years (SEER, CBTRUS 2012). Although the mutant <italic>IDH1</italic> glioma are more amenable to gross-total resection<sup><xref ref-type="bibr" rid="CR11">11</xref></sup> and seem to respond better to standard chemoradiation<sup><xref ref-type="bibr" rid="CR12">12</xref>–<xref ref-type="bibr" rid="CR14">14</xref></sup> especially  when associated 1p/19q co-deletion, the <italic>IDH1</italic> mutations represent a clear opportunity for more targeted treatment either by small-molecule inhibitors of the mutant <italic>IDH1</italic> enzyme<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>, immunotherapy<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>, or by synthetic lethality strategies<sup><xref ref-type="bibr" rid="CR17">17</xref>,<xref ref-type="bibr" rid="CR18">18</xref></sup>. Recently, mutant <italic>IDH1</italic> targeted therapeutic strategies have entered Phase I clinical trials, and neuroimaging can accelerate the clinical translation of these treatments<sup><xref ref-type="bibr" rid="CR19">19</xref>–<xref ref-type="bibr" rid="CR21">21</xref></sup>. Preliminary data from the clinical trials in acute myeloid leukemia (AML) suggest that there is benefit of mutant <italic>IDH2</italic> inhibition and lowering of 2HG concentration<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>, however no data are yet available from clinical trials in mutant <italic>IDH1</italic> glioma patients. Our study sheds light on the metabolic effects in response to mutant <italic>IDH1</italic> inhibition in glioma patients.</p>
              <p id="Par5">The unique biology of 2HG makes this metabolite a very specific biomarker that can be used for the diagnostic, prognostic, prediction, and pharmacodynamics assessment by probing the tumor burden, cancer pathways, and treatment mechanisms in the mutant <italic>IDH1</italic> gliomas. 2HG can be detected noninvasively by in vivo magnetic resonance spectroscopy (MRS), and several methods<sup><xref ref-type="bibr" rid="CR23">23</xref>–<xref ref-type="bibr" rid="CR26">26</xref></sup> have been demonstrated to resolve the spectral overlap between 2HG and other normally occurring brain metabolites. In particular, for monitoring the treatment in mutant <italic>IDH1</italic> glioma patients the non-invasive MRS detection of 2HG is more feasible<sup><xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR28">28</xref></sup> and has clear advantages, compared to biopsies: (1) there are no associated risks, (2) the technique can be repeated multiple times, (3) the technique can probe multiple tumor regions, and (4) MRS can investigate normal appearing brain as internal control. Alternative methods<sup><xref ref-type="bibr" rid="CR29">29</xref>–<xref ref-type="bibr" rid="CR33">33</xref></sup>, such as measuring 2HG in blood, urine, and CSF samples have shown mixed results for mutant <italic>IDH1</italic> glioma, with some studies reporting elevated 2HG only in CSF<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>, while others found elevated 2HG only in urine<sup><xref ref-type="bibr" rid="CR32">32</xref></sup>. The lack of uniform results may be related to lack of a standard protocol with differences in analytical methods, sample collection, and preservation that add to the biological variability. In addition, 2HG levels in periphery are diluted, the spatial localization is lost, tumor heterogeneity cannot be probed, and collecting CSF is not without complication, especially for longitudinal monitoring. Besides tumor production, 2HG levels in serum and urine are also influenced by other factors, such as the blood–brain barrier (BBB), which is less compromised in mutant <italic>IDH1</italic> glioma, and the shedding of tumor material may thus be reduced. The combination of all these factors make the detection of 2HG in CSF, serum, and urine less straightforward in mutant IDH glioma patients, compared to AML patients. On the other hand, MRS methods are rapid, easy to perform, and inexpensive, relative to genomics or other in vivo molecular imaging, such as PET or SPECT. 2HG imaging provides better specificity for detection of <italic>IDH1</italic> mutations than alternative MRI methods<sup><xref ref-type="bibr" rid="CR34">34</xref>–<xref ref-type="bibr" rid="CR39">39</xref></sup>, and could help distinguish true/pseudo-response in treatment assessment<sup><xref ref-type="bibr" rid="CR40">40</xref></sup>. In addition, in the case of mutant <italic>IDH1</italic> inhibitors, 2HG as a direct pharmacodynamic biomarker is expected to probe earliest the target modulation, compared to either conventional anatomical magnetic resonance imaging, such as contrast enhanced T1-weigted and fluid attenuated inversion recovery (FLAIR) MRI that are part of RANO criteria<sup><xref ref-type="bibr" rid="CR41">41</xref>,<xref ref-type="bibr" rid="CR42">42</xref></sup> or the more advanced diffusion/perfusion MRI<sup><xref ref-type="bibr" rid="CR43">43</xref></sup>.</p>
              <p id="Par6">In this study we used a recently demonstrated 3D MRS imaging (MRSI) method for 2HG detection<sup><xref ref-type="bibr" rid="CR27">27</xref></sup> to assess the pharmacodynamic effects of the new investigational drug IDH305 (Novartis Pharmaceuticals) in mutant <italic>IDH1</italic> glioma patients enrolled in an open label first-in-human Phase I clinical trial (ClinicalTrials.gov identifier: NCT02381886). IDH305 is an orally available, brain penetrant, mutant-selective allosteric high affinity <italic>IDH1</italic> inhibitor that acts on both canonical (R132H) and non-canonical (R132C) mutated enzymes, but has much lower affinity for wild-type <italic>IDH1</italic> or mutant <italic>IDH2</italic> enzymes. IDH305 potently reduces the 2HG production in preclinical models, in which a single dose of 100 mg/kg is sufficient to reduce the tumor 2HG levels by 95% in nude mice with <italic>IDH1</italic> mutant flank tumors, and has shown in vitro antiproliferative effects (Novartis Pharmaceuticals Phase I clinical trial protocol, ClinicalTrials.gov identifier: NCT02381886). Hence, the biological effects of IDH305 in patients are expected to be restricted to tumor cells harboring <italic>IDH1</italic>-R132 mutations. Here, we show initial evidence regarding the pharmacodynamic effects of mutant <italic>IDH1</italic> inhibition in glioma patients. Our primary goal in this study was to probe whether IDH305 can modulate target activity in glioma patients. In addition to 2HG, we measured other metabolites that are coupled with 2HG production, such as glutamate, glutamine, glutathione, and lactate. We investigated the relation between the change in 2HG levels and other metabolites, and the correlation with other imaging parameters such as tumor volumetrics, and apparent diffusion coefficient (ADC). The scope of this analysis was to uncover the mechanisms that explain the action of the mutant <italic>IDH1</italic> inhibitors in glioma patients, and determine a comprehensive panel of imaging biomarkers that can be used to objectively assess the response to mutant <italic>IDH1</italic> inhibition. By combining genetics, pharmacology, and radiology, we demonstrate a comprehensive strategy, which we name <italic>radiopharmacodynamics</italic>, that can be used for precision and personalized medicine.</p>
            </sec>
            <sec id="Sec2" sec-type="results">
              <title>Results</title>
              <sec id="Sec3">
                <title>Histological grading and molecular subtyping of patients</title>
                <p id="Par7">Eight patients were enrolled in Phase I clinical trial of IDH305 at our institution. Distribution of patients based on the 2016 WHO classification<sup><xref ref-type="bibr" rid="CR3">3</xref></sup> was two grade II, five grade III, and one grade IV. Table <xref rid="Tab1" ref-type="table">1</xref> lists the demographics, histological grading/typing and the molecular subtyping, FLAIR and 2HG levels at baseline for all the patients.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Demographic, histology and molecular markers of patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Pt</th><th>A/G</th><th>Grade</th><th>Type</th><th><italic>IDH1</italic></th><th>IDH305</th><th>1p/19q</th><th>TP53</th><th>MGMT</th><th>FLAIR (cm<sup>3</sup>)</th><th>2HG (mM)</th></tr></thead><tbody><tr><td>#1</td><td>49/F</td><td>III</td><td>AOD</td><td>R132H</td><td>550 mg</td><td>co-del</td><td>n.a.</td><td>n.a.</td><td>15.9</td><td>2.32</td></tr><tr><td>#2</td><td>48/F</td><td>II</td><td>A</td><td>R132H</td><td>550 mg</td><td>n.d.</td><td>mut</td><td>n.a.</td><td>23.7</td><td>0.28</td></tr><tr><td>#3</td><td>30/F</td><td>IV</td><td>GBM</td><td>R132H</td><td>550 mg</td><td>co-del</td><td>n.a.</td><td>met</td><td>7.9</td><td>1.73</td></tr><tr><td>#4</td><td>42/M</td><td>III</td><td>AA</td><td>R132H</td><td>550 mg</td><td>not-del</td><td>mut</td><td>umet</td><td>10.3</td><td>0.59</td></tr><tr><td>#5</td><td>38/M</td><td>III</td><td>AA</td><td>R132H</td><td>550 mg</td><td>not-del</td><td>mut</td><td>umet</td><td>8.8</td><td>1.04</td></tr><tr><td>#6</td><td>49/F</td><td>III</td><td>AA</td><td>R132H</td><td>550 mg</td><td>co-del</td><td>n.a.</td><td>n.a.</td><td>43.2</td><td>1.31</td></tr><tr><td>#7</td><td>31/M</td><td>III</td><td>AA</td><td>R132H</td><td>900 mg</td><td>not-del</td><td>mut</td><td>n.a.</td><td>3.9</td><td>n.d.</td></tr><tr><td>#8</td><td>46/F</td><td>II</td><td>A*</td><td>R132H</td><td>550 mg</td><td>n.d.</td><td>n.a.</td><td>n.a.</td><td>7.8</td><td>n.d.</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: <italic>Pt </italic>Patient number, <italic>A/G</italic> Age/Gender, <italic>A</italic> Astrocytoma, <italic>AA </italic>Anaplastic Astrocytoma, <italic>AOD</italic> Anaplastic Oligodendroglioma, <italic>GBM</italic> Glioblastoma, IDH1 Isocitrate Dehydrogenase 1, <italic>R132H </italic>Arginine 132 to Histidine, <italic>IDH305</italic> inhibitor of IDH1-R132H, <italic>1p/19q </italic>co-deletion of 1p and 19q chromosome arms, <italic>TP53</italic> Tumor Protein p53, <italic>MGMT</italic><italic>O</italic><sup>6</sup>-Methylguanine DNA Methyltransferase, <italic>FLAIR </italic>Fluid Attenuated Inversion Recovery, <italic>2HG </italic>2-hydroxyglutarate, <italic>co-del</italic> co-delited, <italic>mut</italic> mutated, <italic>met</italic> methylated, <italic>umet</italic> un-methylated, <italic>n.a.</italic>not available<italic>, n.d.</italic> not detectable. Patients 1–5 had baseline and follow-up MRSI scans, patient 6 had only baseline scan, and patients 7–8 had no detectable 2HG at baseline. *According to WHO 2007 this patient was diagnosed as ganglioglioma with atypical features.</p></table-wrap-foot></table-wrap></p>
              </sec>
              <sec id="Sec4">
                <title>Longitudinal metabolic imaging of patients</title>
                <p id="Par8">Longitudinal imaging data was available from five patients (#1–5), all receiving 500 mg of IDH305 orally BID. One patient (#6) had only baseline imaging and did not complete the post treatment scan, while in two other patients (#7 with grade II diffuse astrocytoma, and #8 with grade III anaplastic astrocytoma) the 2HG levels at pretreatment imaging scan were not detectable by MRSI. These two patients (#7 and #8) had the smallest FLAIR volumes among all patients, 3.8 and 7.8 cm<sup>3</sup>, respectively. The 2HG imaging results from these three patients (#6–8) are shown in Supplementary Figure <xref rid="MOESM1" ref-type="media">1</xref>. A recent study has found that MRS detection of 2HG is significantly reduced in patients with FLAIR volumes smaller than 8 cm<sup>3</sup>. The patient with 7.8 cm<sup>3</sup> FLAIR volume had the shortest time interval (2 weeks) between the surgery and the baseline scan, with visible blood products in the surgical cavity. The tumor location in both patients was in a brain region which yielded good quality MRSI (SNR &gt; 5, FWHM &lt; 12 Hz).</p>
                <p id="Par9">Figure <xref rid="Fig1" ref-type="fig">1</xref> shows longitudinal 3D imaging of 2HG and other brain metabolites in glioma patients (#1–5) before and after 1 week of mutant <italic>IDH1</italic> inhibitor treatment with the experimental drug IDH305. Anatomical FLAIR and structural diffusion MR imaging acquired at the same time points are also presented. In the five patients with longitudinal 2HG imaging, the highest levels of 2HG are obtained in the region of FLAIR abnormality at the baseline scan. In some cases, high 2HG levels are noticed further away from the FLAIR region. However, by imposing a threshold on the goodness of fit (Cramer Rao Lower Bounds, CRLB &lt; 25%) for 2HG signal, we obtain the mask with reliable 2HG quantification, as shown in Supplementary Figure <xref rid="MOESM1" ref-type="media">2</xref> where the MRSI voxels remote from the tumor are eliminated.<fig id="Fig1"><label>Fig. 1</label><caption><p>Longitudinal imaging in mutant <italic>IDH1</italic> glioma patients treated with IDH305 inhibitor. <bold>a</bold> Baseline anatomical, structural and metabolic maps before treatment. <bold>b</bold> Follow-up anatomical, structural, and metabolic maps after 1 week of IDH305 treatment. Metabolic maps are converted to mM by reference to healthy creatine levels. The color bars ranges are 0–3 mM (2HG), 0–20 mM (Glx), 0–1 mM (GSH), 0–16 mM (Lac), 0–3 mM (tCho), 0–20 mM (NAA), and 0–4 μm<sup>2</sup>/ms (ADC). On the right, examples of 2HG edited spectra (black trace) and the LCModel fits (red trace) are shown</p></caption><graphic xlink:href="41467_2018_3905_Fig1_HTML" id="d29e1083"/></fig></p>
              </sec>
              <sec id="Sec5">
                <title>Tumor 2HG levels decrease during mutant IDH1 inhibition</title>
                <p id="Par10">The distribution of 2HG values over the tumor volume and how this changed with the treatment was compared using histogram analysis. Histograms of tumor 2HG levels before and after treatment are shown in Fig. <xref rid="Fig2" ref-type="fig">2</xref>. The pretreatment histogram distributions are wider with a right tail toward higher values, while the left tail does not include values that are close to zero. The posttreatment histograms are narrower, shifted toward the left, and are asymmetric having the largest contribution toward zero.<fig id="Fig2"><label>Fig. 2</label><caption><p>Histograms of 2HG levels. The distribution of patient 2HG levels within the tumor ROI are shown before (dashed line) and after 1 week (continuous line) of treatment with the mutant <italic>IDH1</italic> inhibitor IDH305</p></caption><graphic xlink:href="41467_2018_3905_Fig2_HTML" id="d29e1103"/></fig></p>
                <p id="Par11">The fractional change of mean values averaged over the entire tumor region of interest (ROI) is shown in Fig. <xref rid="Fig3" ref-type="fig">3</xref> for 2HG, other brain metabolites, metabolic ratios, the apparent diffusion coefficient (ADC), and the ROI volume. After 1 week of treatment only the levels of 2HG show statistically significant (<italic>P</italic> &lt; 0.05) changes with 70% reduction of the 2HG/hCr ratio (2HG relative to healthy creatine), 57% reduction of the 2HG/tCr ratio (2HG relative to tumor creatine), and 58% reduction of the 2HG/Glx ratio (2HG relative to glutamine + glutamate). There was a trend for an increase in lactate levels (9%), increase in ADC (5%), and increase in FLAIR volume (9%). The median and confidence intervals of pre and posttreatment mean values across five patients are listed in Table <xref rid="Tab2" ref-type="table">2</xref>.<fig id="Fig3"><label>Fig. 3</label><caption><p>Boxplot of the fractional changes for the mean values averaged over the tumor ROI. Box size represents the first and third quartiles, and horizontal red line indicates the median. Statistical significant changes are indicated by the * symbol (<italic>P</italic> &lt; 0.05)</p></caption><graphic xlink:href="41467_2018_3905_Fig3_HTML" id="d29e1126"/></fig><table-wrap id="Tab2"><label>Table 2</label><caption><p>Quantification of metabolites and imaging parameters</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th><bold>2HG/</bold><break/><bold>hCr</bold></th><th><bold>2HG/</bold><break/><bold>tCr</bold></th><th><bold>2HG/</bold><break/><bold>Glx</bold></th><th><bold>GSH/</bold><break/><bold>hCr</bold></th><th><bold>Glx/</bold><break/><bold>hCr</bold></th><th><bold>Lac/</bold><break/><bold>hCr</bold></th><th><bold>tCho/</bold><break/><bold>hCr</bold></th><th><bold>NAA/</bold><break/><bold>hCr</bold></th><th><bold>ADC (mm</bold><sup><bold>2</bold></sup><bold>/ms)</bold></th><th><bold>FLAIR (cm</bold><sup><bold>3</bold></sup><bold>)</bold></th></tr></thead><tbody><tr><td><bold>Pre (median)</bold></td><td>0.131</td><td>0.185</td><td>0.128</td><td>0.045</td><td>1.001</td><td>0.627</td><td>0.244</td><td>0.617</td><td>1.206</td><td>10.295</td></tr><tr><td><bold>Pre (95% CI)</bold></td><td>0.091</td><td>0.163</td><td>0.074</td><td>0.008</td><td>0.133</td><td>0.433</td><td>0.065</td><td>0.130</td><td>0.095</td><td>5.787</td></tr><tr><td><bold>Post (median)</bold></td><td>0.057</td><td>0.102</td><td>0.064</td><td>0.039</td><td>0.974</td><td>0.760</td><td>0.226</td><td>0.626</td><td>1.312</td><td>16.861</td></tr><tr><td><bold>Post (95% CI)</bold></td><td>0.043</td><td>0.078</td><td>0.057</td><td>0.006</td><td>0.217</td><td>0.314</td><td>0.087</td><td>0.220</td><td>0.096</td><td>3.951</td></tr><tr><td><bold><italic>P</italic></bold><bold>-value</bold></td><td>0.019</td><td>0.017</td><td>0.035</td><td>0.263</td><td>0.807</td><td>0.308</td><td>0.706</td><td>0.545</td><td>0.132</td><td>0.173</td></tr></tbody></table><table-wrap-foot><p>Median values, 95% Confidence Intervals (CI), and the <italic>P</italic>-value for the pre-treatment and post-treatment imaging biomarkers. Inhibitors of the mutant isocitrate dehydrogenase 1 (<italic>IDH1</italic>) entered recently in clinical trials for the treatment of gliomas. Here, the authors apply a MRS imaging method for 2HG detection and assessement of the pharmacodynamic effects of the mutant<italic> IDH1</italic> inhibitor (IDH305) in eight mutant<italic> IDH1</italic> glioma patients.</p></table-wrap-foot></table-wrap></p>
                <p id="Par12">In three patients, we had a third follow-up MR scan performed at 1 month after the start of IDH305 therapy. The 2HG levels (2HG/hCr) at 1 month (Median = 0.06, CI = 0.07) and at 1 week (Median = 0.05, CI = 0.03) are similarly decreased, compared to the baseline (Median = 0.21, CI = 0.1). There is increased variability at 1 month because the 2HG levels drop toward the detectability threshold for MRS, hence the precision of our estimates decreases. We have included in Supplementary Figure <xref rid="MOESM1" ref-type="media">3</xref> the 2HG imaging data for the third visit and in Supplementary Figure <xref rid="MOESM1" ref-type="media">4</xref> the plot of 2HG values for all three time points.</p>
              </sec>
              <sec id="Sec6">
                <title>Metabolic reprogramming of mutant IDH1 glioma</title>
                <p id="Par13">Next, we investigated whether there is a relationship between the change in 2HG levels and the metabolites that are coupled with 2HG production. In particular, glutathione, glutamine, and glutamate are a part of the metabolic reactions that are closely connected with the mutant <italic>IDH1</italic> pathway. These metabolites have important cellular roles, GSH is the major scavenger of free radical species required to maintain the redox balance, and glutamine is an anaplerotic source of carbon and nitrogen in the brain. In addition to these, lactate is a metabolite of particular significance in cancer, related to the Warburg effect, and is implicated in many cancer mechanisms.</p>
                <p id="Par14">The increase in lactate levels shown in Fig. <xref rid="Fig3" ref-type="fig">3</xref> may be an important observation associated with the inhibition of mutant <italic>IDH1</italic>. It has been reported that the activity of lactate dehydrogenase A (LDH-A) is downregulated in mutant <italic>IDH1</italic> glioma cells<sup><xref ref-type="bibr" rid="CR44">44</xref></sup>, which is opposite to the typical upregulation of LDH-A in most other cancers.</p>
                <p id="Par15">The mutant <italic>IDH1</italic> couples the reduction of αKG to 2HG with the oxidation of NADPH to NADP<sup>+</sup>. It has been shown that wild-type <italic>IDH1</italic> is the most important source of NADPH in the brain, and the mutant <italic>IDH1</italic> enzyme consumes more NADPH than produced by the wild-type <italic>IDH1</italic> enzyme<sup><xref ref-type="bibr" rid="CR45">45</xref></sup>. In turn, NADPH is used to regenerate the reduced glutathione, and a decrease in NADPH in mutant <italic>IDH1</italic> glioma may lower the GSH levels. Conversely, an increase in NADPH due to inhibition of mutant <italic>IDH1</italic> may result in an increase in GSH levels. A linear model fit in Fig. <xref rid="Fig4" ref-type="fig">4a</xref> shows a trend for inverse correlation between fractional changes of 2HG and GSH levels.<fig id="Fig4"><label>Fig. 4</label><caption><p>Relation between the treatment induced changes of 2HG and other metabolic and imaging biomarkers. Linear model fitting has been employed to investigate the relationship between the changes: <bold>a</bold> 2HG and GSH; <bold>b</bold> 2HG and Glx; <bold>c</bold> ratio of 2HG/Glx and ADC. A significant inverse correlation was found between changes of 2HG/Glx ratio and changes of ADC after 1 week of treatment with IDH305</p></caption><graphic xlink:href="41467_2018_3905_Fig4_HTML" id="d29e1547"/></fig></p>
                <p id="Par16">Glutamine is an important source for tricarboxylic acid cycle anaplerosis in cancer cells<sup><xref ref-type="bibr" rid="CR46">46</xref></sup>, and in the case of mutant <italic>IDH1</italic> glioma cells, glutamine becomes the major source for 2HG synthesis via a two-step process, involving glutamate and αKG as intermediaries<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>. Glutamate and glutamine levels have been found to be lower in mutant <italic>IDH1</italic> compared to wild-type <italic>IDH1</italic> glioma patients, as measured by the mass spectrometry in tumor biopsies<sup><xref ref-type="bibr" rid="CR47">47</xref></sup>. Previously, we found that Glx signal (glutamate + glutamine) by in vivo MRSI is decreased in tumor, compared to contralateral normal appearing white matter in mutant <italic>IDH1</italic> patients. Inhibition of mutant <italic>IDH1</italic> activity might limit the conversion of glutamine into 2HG. Our results from Fig. <xref rid="Fig4" ref-type="fig">4b</xref> indicate a trend for inverse correlation between the fractional changes of 2HG and Glx, however this correlation is weaker than in the case of GSH.</p>
              </sec>
              <sec id="Sec7">
                <title>Correlation of metabolic profile and cellular density</title>
                <p id="Par17">Previous studies<sup><xref ref-type="bibr" rid="CR48">48</xref></sup> have found that 2HG levels correlate with the cellular density of mutant <italic>IDH1</italic> glioma tumors. In this study, we sought to investigate whether the dynamic changes in 2HG levels would correlate with the dynamic changes in cell density during treatment with mutant <italic>IDH1</italic> inhibitors. Since longitudinal biopsies were not available, we correlated the changes in 2HG with the changes in an imaging parameter that is a surrogate biomarker for cell density. The apparent diffusion coefficient is an imaging biomarker that probes tissue microstructure and cell density<sup><xref ref-type="bibr" rid="CR49">49</xref>,<xref ref-type="bibr" rid="CR50">50</xref></sup>. ADC has been shown to increase in tumors that respond to the treatment<sup><xref ref-type="bibr" rid="CR51">51</xref>,<xref ref-type="bibr" rid="CR52">52</xref></sup>. The results of a linear model fit in Fig. <xref rid="Fig4" ref-type="fig">4c</xref> shows that there is a significant inverse correlation between the changes in the 2HG/Glx ratio and the changes in ADC. In the case of mutant <italic>IDH1</italic> inhibition, the simultaneous decrease of the 2HG/Glx ratio and the increase in ADC might be interpreted as a sign of objective treatment response in glioma patients.</p>
              </sec>
            </sec>
            <sec id="Sec8" sec-type="discussion">
              <title>Discussion</title>
              <p id="Par18">Mutations of <italic>IDH1</italic> offer the opportunity to develop an effective treatment against gliomas. The efforts to translate mutant <italic>IDH1</italic>-targeted treatments are significantly enhanced by the existence of the 2HG biomarker that can be measured to assess the objective response rates. However, serial biopsies for pharmacodynamic assessments in glioma patients pose the risks of neurological injury or infection, which in the setting of clinical trials might not outweigh the clinical benefits. Hence, imaging<sup><xref ref-type="bibr" rid="CR53">53</xref></sup> and “liquid biopsies”<sup><xref ref-type="bibr" rid="CR54">54</xref></sup> (blood, urine, and cerebrospinal fluid) remain the only options, at present, to objectively monitor the treatments over time in glioma trials. 2HG is the most informative biomarker on the pharmacodynamics of mutant <italic>IDH1</italic> inhibitors. The intra-tumoral 2HG levels probe directly the in vivo activity of mutant <italic>IDH1</italic> enzyme, while the peripheral 2HG levels are modulated in addition by other factors, such as the BBB. In particular, 3D imaging is well-suited to serially monitor the treatment because it can investigate the entire tumor volume and healthy brain, and it is not affected by sampling bias of single-point measurements. Hence, precision medicine-based clinical trials become feasible in glioma patients, by employing quantitative imaging for pharmacodynamic biomarker assessment in longitudinal studies.</p>
              <p id="Par19">The molecular mechanisms of the mutant <italic>IDH1</italic> glioma are not fully understood, and the implications of mutant <italic>IDH1</italic> inhibition are still a matter of debate. Earlier, preclinical data demonstrated<sup><xref ref-type="bibr" rid="CR15">15</xref></sup> that the mutant <italic>IDH1</italic> inhibition might be able to revert the histone hypermethylation, but not DNA hypermethylation, induce cell differentiation, and delay tumor growth. Recently, preclinical studies using multiple patient-derived glioma models have failed to show an effect on tumor growth by mutant <italic>IDH1</italic> inhibitors<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>. More importantly, the clinical data show that mutant <italic>IDH1</italic> patients have significantly longer survival compared to wild-type <italic>IDH1</italic> patients<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>, implying some benefit in harboring the <italic>IDH1</italic> mutations either by a more indolent progression or intrinsic vulnerabilities that cause better response to existing therapies<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>.</p>
              <p id="Par20">To unequivocally answer the conundrum regarding the implications of mutant <italic>IDH1</italic> inhibition, it is paramount to probe the target modulation in patients and exclude the lack of in vivo drug activity. Our results demonstrate that IDH305 modulates target activity and is effective in the inhibition of mutant <italic>IDH1</italic>, lowering 2HG levels by 70% after 1 week of treatment. In addition, there are other metabolic effects of mutant <italic>IDH1</italic> inhibition, as suggested by a trend toward an inverse correlation between changes of 2HG and glutathione or glutamine + glutamate, respectively. Opposite changes of 2HG and Glx levels in mutant <italic>IDH1</italic> glioma (i.e., high 2HG and low Glx tumor levels) may make the 2HG/Glx ratio a metabolic biomarker that has an increased range to detect mutant <italic>IDH1</italic> tumor tissue. Although similar to the Cho/NAA ratio (i.e., high Cho and low NAA tumor levels) in wild-type gliomas, the 2HG/Glx ratio may be more specific to detect the targeted treatment response against mutant <italic>IDH1</italic> gliomas. Changes in glutathione levels are particularly relevant in connection with tumor susceptibility to radiotherapy. The biological effects of radiotherapy are amplified by free radical oxygen species, which in turn are neutralized by glutathione. Hence, it has been hypothesized that mutant <italic>IDH1</italic> patients having lower NADPH, and consequently lower GSH levels, would be more radiosensitive<sup><xref ref-type="bibr" rid="CR45">45</xref>,<xref ref-type="bibr" rid="CR55">55</xref></sup>. On the other hand, an increase in GSH due to m<italic>IDH1</italic> inhibition would diminish the radiobiological effects, and may argue against the simultaneous administration of mutant <italic>IDH1</italic> inhibitors and radiotherapy<sup><xref ref-type="bibr" rid="CR56">56</xref></sup>. The correlation between changes of Glx and 2HG is weaker than the one between the changes of GSH and 2HG, which may be explained by the fact that glutamine is used in many metabolic pathways, including being a precursor for the synthesis of GSH. The increase in lactate levels in post-treatment scans could indicate that downregulation of the LDH-A activity is reversible through mutant <italic>IDH1</italic> inhibition. Lactate is thought to play many roles in the pathophysiology of cancer, creating an acidic environment that favors cell migration, immune escape, and epigenetic alterations<sup><xref ref-type="bibr" rid="CR57">57</xref></sup>. On the other hand, we observed a significant correlation between decreasing levels of 2HG/Glx and increasing ADC values. An increase in ADC is associated with a decrease in cellular density, and is regarded as a positive outcome in cancer treatment. Thus, raising lactate levels and increasing ADC values by mutant <italic>IDH1</italic> inhibition poses a puzzling scenario.</p>
              <p id="Par21">In some patients, we noted an increase of the FLAIR volume which raises the question whether these patients experienced tumor progression during the treatment with IDH305. A related question is whether the quantification of 2HG levels is affected by the change in FLAIR volumes. In order to avoid the possible confounding effect due edema and changes in water content in tumor, we quantified 2HG and the other tumor metabolites relative to the levels of creatine in the normal appearing (healthy) brain which is not affected by IDH305, and where no change in FLAIR is noticed. Tumor 2HG levels also decrease when quantified, relative to healthy creatine, which indicate a true 2HG decrease. A true 2HG decrease and the decrease of total choline would reject the tumor progression and would be consistent with pseudo-progression radiographic changes. In addition, no worsening of clinical symptoms, such as progressive headaches were reported by the patients during the course of the study.</p>
              <p id="Par22">Metabolic maps of the mutant IDH glioma patients show that levels of glutamate/glutamine (Glx) and glutathione (GSH) are decreased in the tumor regions compared to the contralateral regions, while lactate is increased in the tumor. However, while 2HG and lactate are focally increased in the tumor, because of lack of background signal in the surrounding tissue, the maps of Glx and GSH show smaller contrast between the tumor and the healthy tissue due to larger background signal of the normal brain. In addition, the longitudinal changes of Glx could be confounded by different fate of glutamate and glutamine in tumor metabolism. Methods<sup><xref ref-type="bibr" rid="CR58">58</xref>–<xref ref-type="bibr" rid="CR61">61</xref></sup> that can separate better the contributions of Glu and Gln in MR spectroscopy might be able to differentiate better whether the inhibition of 2HG in patients is coupled with biochemical pathways of Gln or Glu.</p>
              <p id="Par23">Several limitations exist in our study, the most important being the low number of patients. Phase I clinical trials focused on the safety/toxicity/feasibility are performed on a small cohort of patients, and our imaging data is inherently limited by the design of the Phase I study. In addition, recurrent glioma patients enrolled in the Phase I trial are particularly challenging for 2HG detection, since these patients have a history of multiple prior therapies, including surgical resections. Existing data<sup><xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR28">28</xref></sup> indicate that current chemoradiation therapies are also effective in reducing 2HG levels. Hence, it is expected that the baseline 2HG levels in patients from the Phase I study would be lower than in newly diagnosed patients. In our study, we were not able to detect 2HG levels at baseline in 25% (2/8) of the patients, which was related to small residual tumor postsurgery. With our MRSI protocol, we can reliably detect 2HG concentrations above 1 mM<sup><xref ref-type="bibr" rid="CR62">62</xref></sup>, though lower concentrations (0.1–1 mM) are possible for data of very good spectral quality (linewidth &lt; 6 Hz). Assuming 2HG concentration of 1 mM, tumors that have a volume of 1.9 cm<sup>3</sup> or larger can be detected with our current protocol, but smaller tumors may be detected if they produce higher 2HG levels, or by more data averaging and longer acquisition times. These limitations due to imaging protocol mandates, further the efforts to improve the sensitivity of MRS-based 2HG detection. Another limitation is related to the fact that we do not yet have survival data to correlate with imaging parameters. Hence, we are not able, at this moment, to make any analysis regarding the predictive value of the objective response assessment based on 2HG levels, nor to infer any conclusion regarding the patient benefit. Despite these limitations, our preliminary results from this Phase I study shed light on the metabolic networks that may be impacted in patients by the inhibition of mutant <italic>IDH1</italic>, and potentially guide the future development. Although interesting, our imaging results need to be replicated in a larger cohort of patients.</p>
              <p id="Par24">Our <italic>radiopharmacodynamics</italic> study demonstrates the feasibility of image-based 2HG pharmacodynamic serial assessments in patients treated with mutant <italic>IDH1</italic> inhibitors. Since no animal model entirely recapitulates the human disease, there is no better substitute for human studies to test these drugs. A precision medicine approach is easy to perform by non-invasive longitudinal imaging in glioma patients where serial biopsies have high risks. Although, we found correlation between 2HG levels and widely used imaging parameters, such as ADC, the 2HG measurements are indispensable to probe the target modulation, mechanisms of action, metabolic reprogramming, and further could be used to study the dose-response activity of mutant <italic>IDH1</italic> inhibitors.</p>
              <p id="Par25">2HG measurements have the highest specificity for mutant <italic>IDH1</italic> mutations, and may distinguish true/pseudo-response/progression in the case of standard chemoradiation. However, we would like to caution that in the case of targeted mutant <italic>IDH1</italic> inhibition the interpretation and role of 2HG imaging needs to be carefully evaluated and understood. For example, mutant <italic>IDH1</italic> inhibition could efficiently reduce the 2HG levels, but this may not equate with tumor cell death. This is a situation analogous to that of anti-angiogenic therapy that reduces the contrast enhancement making tumors almost invisible on T1-weighted MRI, although gliomas can persist and progress behind a restored BBB<sup><xref ref-type="bibr" rid="CR40">40</xref></sup>. Thus, decreased 2HG in the setting of mutant <italic>IDH1</italic> inhibition could be similar to reduced BBB leakiness of Gd-based contrast agents in the setting of anti-angiogenic therapy, and the pseudo-response by 2HG imaging might not be excluded. Nevertheless, the possibility of a 2HG imaging pseudo-response is likely to happen only in the case of mutant <italic>IDH1</italic> inhibitors used as monotherapy. In the case of standard chemoradiation, immunotherapy, or combination therapies, a decrease in 2HG is likely to reflect a decrease in tumor cell numbers. On the other hand, an increase of 2HG can rule out pseudo-progression and rule in true-progression. It is interesting to point that our data shows a tendency for larger FLAIR volumes after mutant <italic>IDH1</italic> inhibition, which may suggest either pseudo-progression or true-disease progression. The simultaneous increase of ADC with decrease of 2HG supports, in this case, the pseudo-progression interpretation of imaging findings. 2HG is likely the earliest biomarker of response in the case of mutant <italic>IDH1</italic> inhibition, and a disconnect between 2HG and conventional anatomical imaging is expected. To account for such a complex scenario, a larger panel of imaging biomarkers should be used in addition to 2HG, including other metabolites such as lactate, Glx, choline, NAA, and structural parameters such as ADC.</p>
              <p id="Par26">In summary, we demonstrate that 2HG imaging can inform the phase I clinical trial on the biological effects of targeted therapies against mutant <italic>IDH1</italic> gliomas, and potentially it could be used to guide future trial designs. An early assessment of treatment is important to avoid the possible negative side effects, and steer the course for maximizing patient benefit and quality of life. We expect that our methodology will help efforts of cancer scientists for further rational drug development.</p>
            </sec>
            <sec id="Sec9" sec-type="materials|methods">
              <title>Materials and methods</title>
              <sec id="Sec10">
                <title>Patient population</title>
                <p id="Par27">Patients were enrolled in the imaging study, according to the inclusion/exclusion criteria of the Phase I clinical trial (ClinicalTrials.gov identifier: NCT02381886). Briefly, to be included the patients had to have confirmed <italic>IDH1</italic>-R132 mutant glioma for whom no curative therapy is available and who have evidence of disease progression following a standard therapy. Patients were excluded if they had less than 2 weeks from the last dose of systemic antineoplastic therapy, 6 weeks from bevacizumab, 3 months from radiotherapy, and less than 2 weeks from major surgery. In seven patients the IDH305 was administered at a dose of 550 mg orally twice a day (BID), while in one patient the dose was 900 mg orally BID. Imaging was performed at baseline 1–7 days prior to the start of IDH305, and at follow-up after 7 days of IDH305. The choice of the follow-up time point at 1 week was determined based on the following reasons: (1) a rapid inhibition of m<italic>IDH1</italic> by IDH305 with a large effect size on 2HG levels and (2) unknown toxicity that may limit the duration of IDH305 administration.</p>
              </sec>
              <sec id="Sec11">
                <title>IDH1 mutations</title>
                <p id="Par28"><italic>IDH1</italic>-mutational status was first tested by immunohistochemistry (IHC) analysis using an anti-human R132H antibody (DIANOVA)<sup><xref ref-type="bibr" rid="CR63">63</xref></sup> and subsequently confirmed by genetic sequencing (SNaPshot)<sup><xref ref-type="bibr" rid="CR64">64</xref>,<xref ref-type="bibr" rid="CR65">65</xref></sup>. Other molecular markers such as 1p/19q codeletion<sup><xref ref-type="bibr" rid="CR66">66</xref></sup> and MGMT promoter methylation<sup><xref ref-type="bibr" rid="CR67">67</xref></sup> were tested using fluorescence in situ hybridization (FISH) and polymerase chain reaction (PCR), respectively<sup><xref ref-type="bibr" rid="CR64">64</xref></sup>, while TP53 mutation was confirmed also by SNaPshot<sup><xref ref-type="bibr" rid="CR64">64</xref>,<xref ref-type="bibr" rid="CR65">65</xref></sup>.</p>
              </sec>
              <sec id="Sec12">
                <title>Imaging protocol</title>
                <p id="Par29">MRI and MRSI data were acquired on a clinical 3T MR scanner (Tim Trio, Siemens, Erlangen) with a 32-channel head coil. A recently developed spectral-editing 3D MRSI sequence was used for metabolic imaging as following. Two spectral editing 3D MRSI acquisitions were performed (1) for 2HG detection<sup><xref ref-type="bibr" rid="CR27">27</xref></sup> with MEGA editing pulses applied at 1.9 ppm (ON) and 7.5 ppm (OFF) and (2) for GSH detection<sup><xref ref-type="bibr" rid="CR68">68</xref></sup> with MEGA editing pulses applied at 4.57 ppm (ON) and −1 ppm. Other acquisition parameters of 3D MRSI were: MEGA-LASER spectral editing, spiral k-space readout, TR = 1600 ms, TE = 68 ms, FOV = 200 × 200 × 200 mm<sup>3</sup>, VOI = 100 × 80 × 50 mm<sup>3</sup>, acquisition matrix 10 × 10 × 10 which was zero filled to 16 × 16 × 16 in the FFT reconstruction, yielding a digital voxel volume of 1.9 cm<sup>3</sup>, acquisition time 9:55 min:s. Second order B0 shimming was performed based on B0 fieldmaps obtained with a double echo gradient sequence. Water suppression was performed with WET scheme<sup><xref ref-type="bibr" rid="CR69">69</xref></sup>. Anatomical and structural MRI was performed using FLAIR (TR/TI/TE = 10000/2500/70 ms, FOV = 220 × 186 × 138 mm<sup>3</sup>, matrix = 256 × 192 × 23) and diffusion tensor imaging (TR/TE = 7980/84 ms, <italic>b</italic>-values = 0/700 s/mm<sup>2</sup>, gradient directions = 12, FOV = 236 × 236 × 118 mm<sup>3</sup>, matrix = 128 × 128 × 64). To reproduce the positioning across visits for each patient, the online automatic slice positioning (AAscout<sup><xref ref-type="bibr" rid="CR70">70</xref></sup>) was used during acquisition of all imaging data.</p>
              </sec>
              <sec id="Sec13">
                <title>Image analysis</title>
                <p id="Par30">Difference and OFF spectra from the 3D MRSI acquisition were fitted with LCModel<sup><xref ref-type="bibr" rid="CR71">71</xref></sup> software using the corresponding simulated basis sets for the MEGA-LASER sequence. Difference spectra were used to quantify 2HG, Glx (glutamate and glutamine), and glutathione (GSH). The OFF spectra were used to quantify the total choline (tCho), creatine (Cr), lactate (Lac), and N-acetyl-aspartate (NAA). Linewidth less than 0.1 ppm (12 Hz) and Cramer-Rao lower bound (CRLB) less than 25% was considered for goodness of fit of 2HG, Glx, and GSH in difference spectra. CRLB less than 20% was considered for the goodness of fit of tCho, Cr, Lac, and NAA in OFF spectra. The 3D metabolic maps were reconstructed using a combination of MINC (Montreal Neurological Institute), FSL (FMRIB Software Library, Oxford, UK), and MATLAB (Mathworks, Natick, MA) software tools. For all metabolites, relative maps were calculated by dividing the metabolite to healthy creatine (hCr) averaged in a ROI situated in contralateral normal appearing white matter. Healthy creatine levels were assumed to be 8 mM, and this was used to convert the units of the relative metabolic maps to mM concentration units. For 2HG, relative maps were calculated also relative to the creatine (2HG/tCr) and Glx in the tumor. Tumor ROIs were manually outlined around the hyperintense areas in the FLAIR images. Healthy ROIs were drawn in contralateral hemisphere in a region that appeared normal on FLAIR images. Using the upper threshold for CRLB (&lt;25%), we obtained the ROI masks that select the voxels with reliable 2HG quantification. The ROIs for tumor, normal appearing white matter, and the 2HG goodness of fit mask (CRLB &lt; 25%) are shown in Supplementary Figure <xref rid="MOESM1" ref-type="media">1</xref>.</p>
              </sec>
              <sec id="Sec14">
                <title>Statistical analysis</title>
                <p id="Par31">Differences in imaging biomarkers between post- and pre-treatment scans were deemed significant at a level of <italic>P</italic> &lt; 0.05 using two-sided paired Student’s <italic>t</italic>-test. The data normality was verified with Kolmogorov-Smirnov test. Correlations between 2HG and other imaging biomarkers were calculated using Pearson product-moment correlation coefficient. Linear model fit was employed to establish the relation between 2HG and other biomarkers. All statistical analysis was performed with the statistical package of MATLAB.</p>
              </sec>
              <sec id="Sec15">
                <title>Data and materials availability</title>
                <p id="Par32">The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.</p>
              </sec>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Electronic supplementary material</title>
              <sec id="Sec16">
                <p>
                  <supplementary-material content-type="local-data" id="MOESM1">
                    <media xlink:href="41467_2018_3905_MOESM1_ESM.pdf">
                      <caption>
                        <p>Supplementary Information</p>
                      </caption>
                    </media>
                  </supplementary-material>
                </p>
              </sec>
            </sec>
          </body>
          <back>
            <fn-group>
              <fn>
                <p>
                  <bold>Electronic supplementary material</bold>
                </p>
                <p><bold>Supplementary Information</bold> accompanies this paper at 10.1038/s41467-018-03905-6.</p>
              </fn>
              <fn>
                <p><bold>Publisher's note:</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
              </fn>
            </fn-group>
            <ack>
              <title>Acknowledgements</title>
              <p>We acknowledge the translational clinical oncology early drug development team at Novartis for developing the IDH305 inhibitor drug. We thank Drs. Kourosh Jafari-Khouzani and Morteza Esmaeili for assistance with some of the patient imaging. We thank Dr. Marjanska Malgorzata for help with the LCModel basis set for MEGA-ASER spectral editing.This work was funded by the National Cancer Institute (NCI/NIH) grants K22CA178269 and R01CA211080 (O.C.A); NIH/NCI Brain Cancer SPORE P50 CA165962 (Project 3, D.P.C.); NIH/NCI R01CA129371 and K24CA125440A (T.T.B.); NIH S10RR013026, S10RR021110, S10RR023401 (B.R.R.).</p>
            </ack>
            <notes notes-type="author-contribution">
              <title>Author contributions</title>
              <p>O.C.A., I.C.A.R., E.R.G., J.D., A.S.C., B.R.R., P.Y.W., D.P.C., and T.T.B. designed research; O.C.A., I.K.N.L., K.R., and E.M.R. performed research; W.B. contributed in the technical development of 2HG imaging; A.J.I. contributed molecular assays for IDH mutation; O.C.A., D.P.C., and T.T.B. analyzed data; all authors reviewed the results and wrote the paper.</p>
            </notes>
            <notes notes-type="COI-statement">
              <sec id="FPar1">
                <title>Competing interests</title>
                <p id="Par33">T.T.B. received consulting honoraria from Merck &amp; Co., Roche, Kirin Pharmaceuticals, Spectrum, Amgen, and Novartis. The other authors declare no competing interests.</p>
              </sec>
            </notes>
            <ref-list id="Bib1">
              <title>References</title>
              <ref id="CR1">
                <label>1.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Parsons</surname>
                      <given-names>DW</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>An integrated genomic analysis of human glioblastoma multiforme</article-title>
                  <source>Science</source>
                  <year>2008</year>
                  <volume>321</volume>
                  <fpage>1807</fpage>
                  <lpage>1812</lpage>
                  <pub-id pub-id-type="doi">10.1126/science.1164382</pub-id>
                  <?supplied-pmid 18772396?>
                  <pub-id pub-id-type="pmid">18772396</pub-id>
                </element-citation>
              </ref>
              <ref id="CR2">
                <label>2.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Yan</surname>
                      <given-names>H</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title><italic>IDH1</italic> and IDH2 mutations in gliomas</article-title>
                  <source>New Engl. J. Med.</source>
                  <year>2009</year>
                  <volume>360</volume>
                  <fpage>765</fpage>
                  <lpage>773</lpage>
                  <pub-id pub-id-type="doi">10.1056/NEJMoa0808710</pub-id>
                  <?supplied-pmid 19228619?>
                  <pub-id pub-id-type="pmid">19228619</pub-id>
                </element-citation>
              </ref>
              <ref id="CR3">
                <label>3.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Louis</surname>
                      <given-names>DN</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>The2016 World Health Organization classification of tumors of the central nervous system: a summary</article-title>
                  <source>Acta Neuropathol.</source>
                  <year>2016</year>
                  <volume>131</volume>
                  <fpage>803</fpage>
                  <lpage>820</lpage>
                  <pub-id pub-id-type="doi">10.1007/s00401-016-1545-1</pub-id>
                  <?supplied-pmid 27157931?>
                  <pub-id pub-id-type="pmid">27157931</pub-id>
                </element-citation>
              </ref>
              <ref id="CR4">
                <label>4.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Dang</surname>
                      <given-names>L</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Cancer-associated <italic>IDH1</italic> mutations produce 2-hydroxyglutarate</article-title>
                  <source>Nature</source>
                  <year>2009</year>
                  <volume>462</volume>
                  <fpage>739</fpage>
                  <lpage>744</lpage>
                  <pub-id pub-id-type="doi">10.1038/nature08617</pub-id>
                  <?supplied-pmid 19935646?>
                  <pub-id pub-id-type="pmid">19935646</pub-id>
                </element-citation>
              </ref>
              <ref id="CR5">
                <label>5.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Xu</surname>
                      <given-names>W</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate dependent dioxygenases</article-title>
                  <source>Cancer Cell</source>
                  <year>2011</year>
                  <volume>19</volume>
                  <fpage>17</fpage>
                  <lpage>30</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.ccr.2010.12.014</pub-id>
                  <?supplied-pmid 21251613?>
                  <pub-id pub-id-type="pmid">21251613</pub-id>
                </element-citation>
              </ref>
              <ref id="CR6">
                <label>6.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Noushmehr</surname>
                      <given-names>H</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma</article-title>
                  <source>Cancer Cell</source>
                  <year>2010</year>
                  <volume>17</volume>
                  <fpage>510</fpage>
                  <lpage>522</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.ccr.2010.03.017</pub-id>
                  <?supplied-pmid 20399149?>
                  <pub-id pub-id-type="pmid">20399149</pub-id>
                </element-citation>
              </ref>
              <ref id="CR7">
                <label>7.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Turcan</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title><italic>IDH1</italic> mutation is sufficient to establish the glioma hypermethylator phenotype</article-title>
                  <source>Nature</source>
                  <year>2012</year>
                  <volume>483</volume>
                  <fpage>479</fpage>
                  <lpage>483</lpage>
                  <pub-id pub-id-type="doi">10.1038/nature10866</pub-id>
                  <?supplied-pmid 22343889?>
                  <pub-id pub-id-type="pmid">22343889</pub-id>
                </element-citation>
              </ref>
              <ref id="CR8">
                <label>8.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Chowdhury</surname>
                      <given-names>R</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases</article-title>
                  <source>Embo. Rep.</source>
                  <year>2011</year>
                  <volume>12</volume>
                  <fpage>463</fpage>
                  <lpage>469</lpage>
                  <pub-id pub-id-type="doi">10.1038/embor.2011.43</pub-id>
                  <?supplied-pmid 21460794?>
                  <pub-id pub-id-type="pmid">21460794</pub-id>
                </element-citation>
              </ref>
              <ref id="CR9">
                <label>9.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lu</surname>
                      <given-names>C</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>IDH mutation impairs histone demethylation and results in a block to cell differentiation</article-title>
                  <source>Nature</source>
                  <year>2012</year>
                  <volume>483</volume>
                  <fpage>474</fpage>
                  <lpage>478</lpage>
                  <pub-id pub-id-type="doi">10.1038/nature10860</pub-id>
                  <?supplied-pmid 22343901?>
                  <pub-id pub-id-type="pmid">22343901</pub-id>
                </element-citation>
              </ref>
              <ref id="CR10">
                <label>10.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Koivunen</surname>
                      <given-names>P</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation</article-title>
                  <source>Nature</source>
                  <year>2012</year>
                  <volume>483</volume>
                  <fpage>484</fpage>
                  <lpage>488</lpage>
                  <pub-id pub-id-type="doi">10.1038/nature10898</pub-id>
                  <?supplied-pmid 22343896?>
                  <pub-id pub-id-type="pmid">22343896</pub-id>
                </element-citation>
              </ref>
              <ref id="CR11">
                <label>11.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Beiko</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title><italic>IDH1</italic> mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection</article-title>
                  <source>Neuro. Oncol.</source>
                  <year>2014</year>
                  <volume>16</volume>
                  <fpage>81</fpage>
                  <lpage>91</lpage>
                  <pub-id pub-id-type="doi">10.1093/neuonc/not159</pub-id>
                  <?supplied-pmid 24305719?>
                  <pub-id pub-id-type="pmid">24305719</pub-id>
                </element-citation>
              </ref>
              <ref id="CR12">
                <label>12.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cairncross</surname>
                      <given-names>JG</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH</article-title>
                  <source>J. Clin. Oncol.</source>
                  <year>2014</year>
                  <volume>32</volume>
                  <fpage>783</fpage>
                  <lpage>790</lpage>
                  <pub-id pub-id-type="doi">10.1200/JCO.2013.49.3726</pub-id>
                  <?supplied-pmid 24516018?>
                  <pub-id pub-id-type="pmid">24516018</pub-id>
                </element-citation>
              </ref>
              <ref id="CR13">
                <label>13.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kizilbash</surname>
                      <given-names>SH</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>The impact of concurrent temozolomide with adjuvant radiation and IDH mutation status among patients with anaplastic astrocytoma</article-title>
                  <source>J. Neurooncol.</source>
                  <year>2014</year>
                  <volume>120</volume>
                  <fpage>85</fpage>
                  <lpage>93</lpage>
                  <pub-id pub-id-type="doi">10.1007/s11060-014-1520-4</pub-id>
                  <?supplied-pmid 24993250?>
                  <pub-id pub-id-type="pmid">24993250</pub-id>
                </element-citation>
              </ref>
              <ref id="CR14">
                <label>14.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Tran</surname>
                      <given-names>AN</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Increased sensitivity to radiochemotherapy in <italic>IDH1</italic> mutant glioblastoma as demonstrated by serial quantitative MR volumetry</article-title>
                  <source>Neuro. Oncol.</source>
                  <year>2014</year>
                  <volume>16</volume>
                  <fpage>414</fpage>
                  <lpage>420</lpage>
                  <pub-id pub-id-type="doi">10.1093/neuonc/not198</pub-id>
                  <?supplied-pmid 24305712?>
                  <pub-id pub-id-type="pmid">24305712</pub-id>
                </element-citation>
              </ref>
              <ref id="CR15">
                <label>15.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Rohle</surname>
                      <given-names>D</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>An inhibitor of mutant <italic>IDH1</italic> delays growth and promotes differentiation of glioma cells</article-title>
                  <source>Science</source>
                  <year>2013</year>
                  <volume>340</volume>
                  <fpage>626</fpage>
                  <lpage>630</lpage>
                  <pub-id pub-id-type="doi">10.1126/science.1236062</pub-id>
                  <?supplied-pmid 23558169?>
                  <pub-id pub-id-type="pmid">23558169</pub-id>
                </element-citation>
              </ref>
              <ref id="CR16">
                <label>16.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Schumacher</surname>
                      <given-names>T</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>A vaccine targeting mutant <italic>IDH1</italic> induces antitumour immunity</article-title>
                  <source>Nature</source>
                  <year>2014</year>
                  <volume>512</volume>
                  <fpage>324</fpage>
                  <lpage>327</lpage>
                  <pub-id pub-id-type="doi">10.1038/nature13387</pub-id>
                  <?supplied-pmid 25043048?>
                  <pub-id pub-id-type="pmid">25043048</pub-id>
                </element-citation>
              </ref>
              <ref id="CR17">
                <label>17.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sulkowski</surname>
                      <given-names>PL</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity</article-title>
                  <source>Sci. Transl. Med.</source>
                  <year>2017</year>
                  <volume>9</volume>
                  <fpage>eaal2463</fpage>
                  <pub-id pub-id-type="doi">10.1126/scitranslmed.aal2463</pub-id>
                  <?supplied-pmid 28148839?>
                  <pub-id pub-id-type="pmid">28148839</pub-id>
                </element-citation>
              </ref>
              <ref id="CR18">
                <label>18.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Tateishi</surname>
                      <given-names>K</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Extreme vulnerability of <italic>IDH1</italic> mutant cancers to NAD+depletion targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas</article-title>
                  <source>Cancer Cell</source>
                  <year>2015</year>
                  <volume>28</volume>
                  <fpage>773</fpage>
                  <lpage>784</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.ccell.2015.11.006</pub-id>
                  <?supplied-pmid 26678339?>
                  <pub-id pub-id-type="pmid">26678339</pub-id>
                </element-citation>
              </ref>
              <ref id="CR19">
                <label>19.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Reardon</surname>
                      <given-names>DA</given-names>
                    </name>
                    <name>
                      <surname>Ballman</surname>
                      <given-names>KV</given-names>
                    </name>
                    <name>
                      <surname>Buckner</surname>
                      <given-names>JC</given-names>
                    </name>
                    <name>
                      <surname>Chang</surname>
                      <given-names>SM</given-names>
                    </name>
                    <name>
                      <surname>Ellingson</surname>
                      <given-names>BM</given-names>
                    </name>
                  </person-group>
                  <article-title>Impact of imaging measurements on response assessment in glioblastoma clinical trials</article-title>
                  <source>Neuro. Oncol.</source>
                  <year>2014</year>
                  <volume>16</volume>
                  <fpage>vii24</fpage>
                  <lpage>vii35</lpage>
                  <pub-id pub-id-type="doi">10.1093/neuonc/nou286</pub-id>
                  <?supplied-pmid 25313236?>
                  <pub-id pub-id-type="pmid">25313236</pub-id>
                </element-citation>
              </ref>
              <ref id="CR20">
                <label>20.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ellingson</surname>
                      <given-names>BM</given-names>
                    </name>
                    <name>
                      <surname>Bendszus</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Sorensen</surname>
                      <given-names>AG</given-names>
                    </name>
                    <name>
                      <surname>Pope</surname>
                      <given-names>WB</given-names>
                    </name>
                  </person-group>
                  <article-title>Emerging techniques and technologies in brain tumor imaging</article-title>
                  <source>Neuro. Oncol.</source>
                  <year>2014</year>
                  <volume>16</volume>
                  <fpage>vii12</fpage>
                  <lpage>vii23</lpage>
                  <pub-id pub-id-type="doi">10.1093/neuonc/nou221</pub-id>
                  <?supplied-pmid 25313234?>
                  <pub-id pub-id-type="pmid">25313234</pub-id>
                </element-citation>
              </ref>
              <ref id="CR21">
                <label>21.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sullivan</surname>
                      <given-names>DC</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Metrology standards for quantitative imaging biomarkers</article-title>
                  <source>Radiology</source>
                  <year>2015</year>
                  <volume>277</volume>
                  <fpage>813</fpage>
                  <lpage>825</lpage>
                  <pub-id pub-id-type="doi">10.1148/radiol.2015142202</pub-id>
                  <?supplied-pmid 26267831?>
                  <pub-id pub-id-type="pmid">26267831</pub-id>
                </element-citation>
              </ref>
              <ref id="CR22">
                <label>22.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Upadhyay</surname>
                      <given-names>VA</given-names>
                    </name>
                    <name>
                      <surname>Brunner</surname>
                      <given-names>AM</given-names>
                    </name>
                    <name>
                      <surname>Fathi</surname>
                      <given-names>AT</given-names>
                    </name>
                  </person-group>
                  <article-title>Isocitrate dehydrogenase (IDH) inhibition as treatment of myeloid malignancies: progress and future directions</article-title>
                  <source>Pharmacol. Ther.</source>
                  <year>2017</year>
                  <volume>14</volume>
                  <fpage>30083</fpage>
                  <lpage>30089</lpage>
                </element-citation>
              </ref>
              <ref id="CR23">
                <label>23.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Choi</surname>
                      <given-names>C</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>2-Hydroxyglutarate detection by magnetic resonance spectroscopy in subjects with IDH-mutated gliomas</article-title>
                  <source>Nat. Med.</source>
                  <year>2012</year>
                  <volume>18</volume>
                  <fpage>624</fpage>
                  <lpage>629</lpage>
                  <pub-id pub-id-type="doi">10.1038/nm.2682</pub-id>
                  <?supplied-pmid 22281806?>
                  <pub-id pub-id-type="pmid">22281806</pub-id>
                </element-citation>
              </ref>
              <ref id="CR24">
                <label>24.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Andronesi</surname>
                      <given-names>OC</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy</article-title>
                  <source>Sci. Transl. Med.</source>
                  <year>2012</year>
                  <volume>4</volume>
                  <fpage>116ra114</fpage>
                  <pub-id pub-id-type="doi">10.1126/scitranslmed.3002693</pub-id>
                </element-citation>
              </ref>
              <ref id="CR25">
                <label>25.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Emir</surname>
                      <given-names>UE</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Noninvasive quantification of 2-hydroxyglutarate in human gliomas with <italic>IDH1</italic> and IDH2 mutations</article-title>
                  <source>Cancer Res.</source>
                  <year>2016</year>
                  <volume>76</volume>
                  <fpage>43</fpage>
                  <lpage>49</lpage>
                  <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-15-0934</pub-id>
                  <?supplied-pmid 26669865?>
                  <pub-id pub-id-type="pmid">26669865</pub-id>
                </element-citation>
              </ref>
              <ref id="CR26">
                <label>26.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kalinina</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Detection of “oncometabolite” 2-hydroxyglutarate by magnetic resonance analysis as a biomarker of <italic>IDH1</italic>/2 mutations in glioma</article-title>
                  <source>J. Mol. Med. (Berl.)</source>
                  <year>2012</year>
                  <volume>90</volume>
                  <fpage>1161</fpage>
                  <lpage>1171</lpage>
                  <pub-id pub-id-type="doi">10.1007/s00109-012-0888-x</pub-id>
                  <pub-id pub-id-type="pmid">22426639</pub-id>
                </element-citation>
              </ref>
              <ref id="CR27">
                <label>27.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Andronesi</surname>
                      <given-names>OC</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Treatment response assessment in IDH-mutant glioma patients by non-invasive 3D functional spectroscopic mapping of 2-hydroxyglutarate</article-title>
                  <source>Clin. Cancer Res.</source>
                  <year>2016</year>
                  <volume>22</volume>
                  <fpage>1632</fpage>
                  <lpage>1641</lpage>
                  <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-15-0656</pub-id>
                  <?supplied-pmid 26534967?>
                  <pub-id pub-id-type="pmid">26534967</pub-id>
                </element-citation>
              </ref>
              <ref id="CR28">
                <label>28.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Choi</surname>
                      <given-names>C</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Prospective longitudinal analysis of 2-hydroxyglutarate magnetic resonance spectroscopy identifies broad clinical utility for the management of patients with IDH-mutant glioma</article-title>
                  <source>J. Clin. Oncol.</source>
                  <year>2016</year>
                  <volume>34</volume>
                  <fpage>4030</fpage>
                  <lpage>4039</lpage>
                  <pub-id pub-id-type="doi">10.1200/JCO.2016.67.1222</pub-id>
                  <?supplied-pmid 28248126?>
                  <pub-id pub-id-type="pmid">28248126</pub-id>
                </element-citation>
              </ref>
              <ref id="CR29">
                <label>29.</label>
                <mixed-citation publication-type="other">Nakamizo, S. et al. GC/MS-based metabolomic analysis of cerebrospinal fluid (CSF) from glioma patients. <italic>J Neurooncol.</italic>10.1007/s11060-013-1090-x (2013).</mixed-citation>
              </ref>
              <ref id="CR30">
                <label>30.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lombardi</surname>
                      <given-names>G</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Diagnostic value of plasma and urinary 2-hydroxyglutarate to identify patients with isocitrate dehydrogenase-mutated glioma</article-title>
                  <source>Oncologist</source>
                  <year>2015</year>
                  <volume>20</volume>
                  <fpage>562</fpage>
                  <lpage>567</lpage>
                  <pub-id pub-id-type="doi">10.1634/theoncologist.2014-0266</pub-id>
                  <?supplied-pmid 25862748?>
                  <pub-id pub-id-type="pmid">25862748</pub-id>
                </element-citation>
              </ref>
              <ref id="CR31">
                <label>31.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Capper</surname>
                      <given-names>D</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>2-Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with <italic>IDH1</italic>/2 mutation status or tumor size</article-title>
                  <source>Int. J. Cancer</source>
                  <year>2012</year>
                  <volume>131</volume>
                  <fpage>766</fpage>
                  <lpage>768</lpage>
                  <pub-id pub-id-type="doi">10.1002/ijc.26425</pub-id>
                  <?supplied-pmid 21913188?>
                  <pub-id pub-id-type="pmid">21913188</pub-id>
                </element-citation>
              </ref>
              <ref id="CR32">
                <label>32.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Fathi</surname>
                      <given-names>AT</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Elevation of urinary 2-hydroxyglutarate in IDH-mutant glioma</article-title>
                  <source>Oncologist</source>
                  <year>2016</year>
                  <volume>1</volume>
                  <fpage>2015</fpage>
                  <lpage>0342</lpage>
                </element-citation>
              </ref>
              <ref id="CR33">
                <label>33.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kalinina</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Selective detection of the D-enantiomer of 2-hydroxyglutarate in the CSF of glioma patients with mutated isocitrate dehydrogenase</article-title>
                  <source>Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res.</source>
                  <year>2016</year>
                  <volume>22</volume>
                  <fpage>6256</fpage>
                  <lpage>6265</lpage>
                  <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-15-2965</pub-id>
                </element-citation>
              </ref>
              <ref id="CR34">
                <label>34.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Carrillo</surname>
                      <given-names>JA</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Relationship between tumor enhancement, edema, <italic>IDH1</italic> mutational status, MGMT promoter methylation, and survival in glioblastoma</article-title>
                  <source>Am. J. Neuroradiol.</source>
                  <year>2012</year>
                  <volume>33</volume>
                  <fpage>1349</fpage>
                  <lpage>1355</lpage>
                  <pub-id pub-id-type="doi">10.3174/ajnr.A2950</pub-id>
                  <?supplied-pmid 22322613?>
                  <pub-id pub-id-type="pmid">22322613</pub-id>
                </element-citation>
              </ref>
              <ref id="CR35">
                <label>35.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lee</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Evaluation of the microenvironmental heterogeneity in high-grade gliomas with <italic>IDH1</italic>/2 gene mutation using histogram analysis of diffusion-weighted imaging and dynamic-susceptibility contrast perfusion imaging</article-title>
                  <source>J. Neurooncol.</source>
                  <year>2014</year>
                  <volume>121</volume>
                  <fpage>141</fpage>
                  <lpage>150</lpage>
                  <pub-id pub-id-type="doi">10.1007/s11060-014-1614-z</pub-id>
                  <?supplied-pmid 25205290?>
                  <pub-id pub-id-type="pmid">25205290</pub-id>
                </element-citation>
              </ref>
              <ref id="CR36">
                <label>36.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Tan</surname>
                      <given-names>WL</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Can diffusion tensor imaging noninvasively detect <italic>IDH1</italic> gene mutations in astrogliomas? a retrospective study of 112 cases</article-title>
                  <source>Am. J. Neuroradiol.</source>
                  <year>2014</year>
                  <volume>35</volume>
                  <fpage>920</fpage>
                  <lpage>927</lpage>
                  <pub-id pub-id-type="doi">10.3174/ajnr.A3803</pub-id>
                  <?supplied-pmid 24557705?>
                  <pub-id pub-id-type="pmid">24557705</pub-id>
                </element-citation>
              </ref>
              <ref id="CR37">
                <label>37.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kickingereder</surname>
                      <given-names>P</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma</article-title>
                  <source>Sci. Rep.</source>
                  <year>2015</year>
                  <volume>5</volume>
                  <fpage>16238</fpage>
                  <pub-id pub-id-type="doi">10.1038/srep16238</pub-id>
                  <?supplied-pmid 26538165?>
                  <pub-id pub-id-type="pmid">26538165</pub-id>
                </element-citation>
              </ref>
              <ref id="CR38">
                <label>38.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Patel</surname>
                      <given-names>SH</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>T2-FLAIR mismatch, an imaging biomarker for IDH and 1p/19q status in lower-grade gliomas: a TCGA/TCIA project</article-title>
                  <source>Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res.</source>
                  <year>2017</year>
                  <volume>23</volume>
                  <fpage>6078</fpage>
                  <lpage>6085</lpage>
                  <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-17-0560</pub-id>
                </element-citation>
              </ref>
              <ref id="CR39">
                <label>39.</label>
                <mixed-citation publication-type="other">Delfanti, R. L. et al. Imaging correlates for the 2016 update on WHO classification of grade II/III gliomas: implications for IDH, 1p/19q and ATRX status. <italic>J. Neurooncol.</italic>10.1007/s11060-017-2613-7 (2017).</mixed-citation>
              </ref>
              <ref id="CR40">
                <label>40.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Brandsma</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>van den Bent</surname>
                      <given-names>MJ</given-names>
                    </name>
                    <name>
                      <surname>Shim</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Holder</surname>
                      <given-names>CA</given-names>
                    </name>
                    <name>
                      <surname>Olson</surname>
                      <given-names>JJ</given-names>
                    </name>
                  </person-group>
                  <article-title>Pseudoprogression and pseudoresponse in the treatment of gliomas magnetic resonance spectroscopic imaging in the era of pseudoprogression and pseudoresponse in glioblastoma patient management</article-title>
                  <source>Curr. Opin. Neurol.</source>
                  <year>2009</year>
                  <volume>22</volume>
                  <fpage>633</fpage>
                  <lpage>638</lpage>
                  <pub-id pub-id-type="doi">10.1097/WCO.0b013e328332363e</pub-id>
                  <?supplied-pmid 19770760?>
                  <pub-id pub-id-type="pmid">19770760</pub-id>
                </element-citation>
              </ref>
              <ref id="CR41">
                <label>41.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wen</surname>
                      <given-names>PY</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group</article-title>
                  <source>J. Clin. Oncol.</source>
                  <year>2010</year>
                  <volume>28</volume>
                  <fpage>1963</fpage>
                  <lpage>1972</lpage>
                  <pub-id pub-id-type="doi">10.1200/JCO.2009.26.3541</pub-id>
                  <?supplied-pmid 20231676?>
                  <pub-id pub-id-type="pmid">20231676</pub-id>
                </element-citation>
              </ref>
              <ref id="CR42">
                <label>42.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>van den Bent</surname>
                      <given-names>MJ</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas</article-title>
                  <source>Lancet Oncol.</source>
                  <year>2011</year>
                  <volume>12</volume>
                  <fpage>583</fpage>
                  <lpage>593</lpage>
                  <pub-id pub-id-type="doi">10.1016/S1470-2045(11)70057-2</pub-id>
                  <?supplied-pmid 21474379?>
                  <pub-id pub-id-type="pmid">21474379</pub-id>
                </element-citation>
              </ref>
              <ref id="CR43">
                <label>43.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Leu</surname>
                      <given-names>K</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas</article-title>
                  <source>J. Neurooncol.</source>
                  <year>2017</year>
                  <volume>134</volume>
                  <fpage>177</fpage>
                  <lpage>188</lpage>
                  <pub-id pub-id-type="doi">10.1007/s11060-017-2506-9</pub-id>
                  <?supplied-pmid 28547590?>
                  <pub-id pub-id-type="pmid">28547590</pub-id>
                </element-citation>
              </ref>
              <ref id="CR44">
                <label>44.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Chesnelong</surname>
                      <given-names>C</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Lactate dehydrogenase A silencing in IDH mutant gliomas</article-title>
                  <source>Neuro. Oncol.</source>
                  <year>2014</year>
                  <volume>16</volume>
                  <fpage>686</fpage>
                  <lpage>695</lpage>
                  <pub-id pub-id-type="doi">10.1093/neuonc/not243</pub-id>
                  <?supplied-pmid 24366912?>
                  <pub-id pub-id-type="pmid">24366912</pub-id>
                </element-citation>
              </ref>
              <ref id="CR45">
                <label>45.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bleeker</surname>
                      <given-names>FE</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>The prognostic <italic>IDH1</italic> (R132) mutation is associated with reduced NADP(+)-dependent IDH activity in glioblastoma</article-title>
                  <source>Acta Neuropathol.</source>
                  <year>2011</year>
                  <volume>119</volume>
                  <fpage>487</fpage>
                  <lpage>494</lpage>
                  <pub-id pub-id-type="doi">10.1007/s00401-010-0645-6</pub-id>
                </element-citation>
              </ref>
              <ref id="CR46">
                <label>46.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Daye</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Wellen</surname>
                      <given-names>KE</given-names>
                    </name>
                  </person-group>
                  <article-title>Metabolic reprogramming in cancer: unraveling the role of glutamine in tumorigenesis</article-title>
                  <source>Semin. Cell. Dev. Biol.</source>
                  <year>2012</year>
                  <volume>23</volume>
                  <fpage>362</fpage>
                  <lpage>369</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.semcdb.2012.02.002</pub-id>
                  <?supplied-pmid 22349059?>
                  <pub-id pub-id-type="pmid">22349059</pub-id>
                </element-citation>
              </ref>
              <ref id="CR47">
                <label>47.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ohka</surname>
                      <given-names>F</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with <italic>IDH1</italic> mutation</article-title>
                  <source>Tumour Biol.</source>
                  <year>2014</year>
                  <volume>35</volume>
                  <fpage>5911</fpage>
                  <lpage>5920</lpage>
                  <pub-id pub-id-type="doi">10.1007/s13277-014-1784-5</pub-id>
                  <?supplied-pmid 24590270?>
                  <pub-id pub-id-type="pmid">24590270</pub-id>
                </element-citation>
              </ref>
              <ref id="CR48">
                <label>48.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>de la Fuente</surname>
                      <given-names>MI</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma</article-title>
                  <source>Neuro. Oncol.</source>
                  <year>2016</year>
                  <volume>18</volume>
                  <fpage>283</fpage>
                  <lpage>290</lpage>
                  <pub-id pub-id-type="doi">10.1093/neuonc/nov307</pub-id>
                  <?supplied-pmid 26691210?>
                  <pub-id pub-id-type="pmid">26691210</pub-id>
                </element-citation>
              </ref>
              <ref id="CR49">
                <label>49.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kalpathy-Cramer</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Gerstner</surname>
                      <given-names>ER</given-names>
                    </name>
                    <name>
                      <surname>Emblem</surname>
                      <given-names>KE</given-names>
                    </name>
                    <name>
                      <surname>Andronesi</surname>
                      <given-names>OC</given-names>
                    </name>
                    <name>
                      <surname>Rosen</surname>
                      <given-names>B</given-names>
                    </name>
                  </person-group>
                  <article-title>Advanced Magnetic Resonance Imaging of the Physical Processes in Human Glioblastoma</article-title>
                  <source>Cancer Res.</source>
                  <year>2014</year>
                  <volume>74</volume>
                  <fpage>4622</fpage>
                  <lpage>4637</lpage>
                  <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-14-0383</pub-id>
                  <?supplied-pmid 25183787?>
                  <pub-id pub-id-type="pmid">25183787</pub-id>
                </element-citation>
              </ref>
              <ref id="CR50">
                <label>50.</label>
                <mixed-citation publication-type="other">Gillard, J, Waldman, A. &amp; Barker, P. MR spectroscopy in stroke. 168–181 (Cambridge University Press, Cambridge, UK, 2005). .</mixed-citation>
              </ref>
              <ref id="CR51">
                <label>51.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ellingson</surname>
                      <given-names>BM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Functional diffusion maps (fDMs) evaluated before and after radiochemotherapy predict progression-free and overall survival in newly diagnosed glioblastoma</article-title>
                  <source>Neuro. Oncol.</source>
                  <year>2012</year>
                  <volume>14</volume>
                  <fpage>333</fpage>
                  <lpage>343</lpage>
                  <pub-id pub-id-type="doi">10.1093/neuonc/nor220</pub-id>
                  <?supplied-pmid 22270220?>
                  <pub-id pub-id-type="pmid">22270220</pub-id>
                </element-citation>
              </ref>
              <ref id="CR52">
                <label>52.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gerstner</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Chen</surname>
                      <given-names>PJ</given-names>
                    </name>
                    <name>
                      <surname>Batchelor</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Sorensen</surname>
                      <given-names>AG</given-names>
                    </name>
                  </person-group>
                  <article-title>Role of diffusion MRI in the detection of infiltrative glioblastoma after treatment with Cediranib</article-title>
                  <source>Neuro. Oncol.</source>
                  <year>2008</year>
                  <volume>10</volume>
                  <fpage>894</fpage>
                  <lpage>894</lpage>
                </element-citation>
              </ref>
              <ref id="CR53">
                <label>53.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wen</surname>
                      <given-names>PY</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Report of the jumpstarting brain tumor drug development coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, BethesdaMD)</article-title>
                  <source>Neuro. Oncol.</source>
                  <year>2014</year>
                  <volume>16</volume>
                  <fpage>vii36</fpage>
                  <lpage>vii47</lpage>
                  <pub-id pub-id-type="doi">10.1093/neuonc/nou226</pub-id>
                  <?supplied-pmid 25313237?>
                  <pub-id pub-id-type="pmid">25313237</pub-id>
                </element-citation>
              </ref>
              <ref id="CR54">
                <label>54.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Best</surname>
                      <given-names>MG</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Liquid biopsies in patients with diffuse glioma</article-title>
                  <source>Acta Neuropathol.</source>
                  <year>2015</year>
                  <volume>129</volume>
                  <fpage>849</fpage>
                  <lpage>865</lpage>
                  <pub-id pub-id-type="doi">10.1007/s00401-015-1399-y</pub-id>
                  <?supplied-pmid 25720744?>
                  <pub-id pub-id-type="pmid">25720744</pub-id>
                </element-citation>
              </ref>
              <ref id="CR55">
                <label>55.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Li</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation</article-title>
                  <source>Neuro. Oncol.</source>
                  <year>2013</year>
                  <volume>15</volume>
                  <fpage>57</fpage>
                  <lpage>68</lpage>
                  <pub-id pub-id-type="doi">10.1093/neuonc/nos261</pub-id>
                  <?supplied-pmid 23115158?>
                  <pub-id pub-id-type="pmid">23115158</pub-id>
                </element-citation>
              </ref>
              <ref id="CR56">
                <label>56.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Molenaar</surname>
                      <given-names>RJ</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Radioprotection of <italic>IDH1</italic>-mutated cancer cells by the <italic>IDH1</italic>-mutant inhibitor AGI-5198</article-title>
                  <source>Cancer Res.</source>
                  <year>2015</year>
                  <volume>75</volume>
                  <fpage>4790</fpage>
                  <lpage>4802</lpage>
                  <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-14-3603</pub-id>
                  <?supplied-pmid 26363012?>
                  <pub-id pub-id-type="pmid">26363012</pub-id>
                </element-citation>
              </ref>
              <ref id="CR57">
                <label>57.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Romero-Garcia</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Moreno-Altamirano</surname>
                      <given-names>MM</given-names>
                    </name>
                    <name>
                      <surname>Prado-Garcia</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Sanchez-Garcia</surname>
                      <given-names>FJ</given-names>
                    </name>
                  </person-group>
                  <article-title>Lactate contribution to the tumor microenvironment: mechanisms, effects on immune cells and therapeutic relevance</article-title>
                  <source>Front. Immunol.</source>
                  <year>2016</year>
                  <volume>7</volume>
                  <fpage>52</fpage>
                  <pub-id pub-id-type="doi">10.3389/fimmu.2016.00052</pub-id>
                  <?supplied-pmid 26909082?>
                  <pub-id pub-id-type="pmid">26909082</pub-id>
                </element-citation>
              </ref>
              <ref id="CR58">
                <label>58.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kim</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Thompson</surname>
                      <given-names>RB</given-names>
                    </name>
                    <name>
                      <surname>Allen</surname>
                      <given-names>PS</given-names>
                    </name>
                  </person-group>
                  <article-title>Enhancement of spectral editing efficacy of multiple quantum filters in in vivo proton magnetic resonance spectroscopy</article-title>
                  <source>J. Magn. Reson.</source>
                  <year>2012</year>
                  <volume>223</volume>
                  <fpage>90</fpage>
                  <lpage>97</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.jmr.2012.07.017</pub-id>
                  <?supplied-pmid 22975239?>
                  <pub-id pub-id-type="pmid">22975239</pub-id>
                </element-citation>
              </ref>
              <ref id="CR59">
                <label>59.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Zhang</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Shen</surname>
                      <given-names>J</given-names>
                    </name>
                  </person-group>
                  <article-title>Simultaneous quantification of glutamate and glutamine by J-modulated spectroscopy at 3 Tesla</article-title>
                  <source>Magn. Reson. Med.</source>
                  <year>2016</year>
                  <volume>76</volume>
                  <fpage>725</fpage>
                  <lpage>732</lpage>
                  <pub-id pub-id-type="doi">10.1002/mrm.25922</pub-id>
                  <?supplied-pmid 26361892?>
                  <pub-id pub-id-type="pmid">26361892</pub-id>
                </element-citation>
              </ref>
              <ref id="CR60">
                <label>60.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Tkac</surname>
                      <given-names>I</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>In vivo 1H NMR spectroscopy of the human brain at 7 T</article-title>
                  <source>Magn. Reson. Med.</source>
                  <year>2001</year>
                  <volume>46</volume>
                  <fpage>451</fpage>
                  <lpage>456</lpage>
                  <pub-id pub-id-type="doi">10.1002/mrm.1213</pub-id>
                  <?supplied-pmid 11550235?>
                  <pub-id pub-id-type="pmid">11550235</pub-id>
                </element-citation>
              </ref>
              <ref id="CR61">
                <label>61.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Dreher</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>Leibfritz</surname>
                      <given-names>D</given-names>
                    </name>
                  </person-group>
                  <article-title>Detection of homonuclear decoupled in vivo proton NMR spectra using constant time chemical shift encoding: CT-PRESS</article-title>
                  <source>Magn. Reson. Imaging</source>
                  <year>1999</year>
                  <volume>17</volume>
                  <fpage>141</fpage>
                  <lpage>150</lpage>
                  <pub-id pub-id-type="doi">10.1016/S0730-725X(98)00156-8</pub-id>
                  <?supplied-pmid 9888407?>
                  <pub-id pub-id-type="pmid">9888407</pub-id>
                </element-citation>
              </ref>
              <ref id="CR62">
                <label>62.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Jafari-Khouzani</surname>
                      <given-names>K</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutant IDH glioma patients</article-title>
                  <source>Neuro. Oncol.</source>
                  <year>2016</year>
                  <volume>18</volume>
                  <fpage>1569</fpage>
                  <lpage>1578</lpage>
                  <?supplied-pmid 27382115?>
                  <pub-id pub-id-type="pmid">27382115</pub-id>
                </element-citation>
              </ref>
              <ref id="CR63">
                <label>63.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Capper</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Zentgraf</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Balss</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Hartmann</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>von Deimling</surname>
                      <given-names>A</given-names>
                    </name>
                  </person-group>
                  <article-title>Monoclonal antibody specific for <italic>IDH1</italic> R132H mutation</article-title>
                  <source>Acta Neuropathol.</source>
                  <year>2009</year>
                  <volume>118</volume>
                  <fpage>599</fpage>
                  <lpage>601</lpage>
                  <pub-id pub-id-type="doi">10.1007/s00401-009-0595-z</pub-id>
                  <?supplied-pmid 19798509?>
                  <pub-id pub-id-type="pmid">19798509</pub-id>
                </element-citation>
              </ref>
              <ref id="CR64">
                <label>64.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Chi</surname>
                      <given-names>AS</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Prospective, high-throughput molecular profiling of human gliomas</article-title>
                  <source>J. Neurooncol.</source>
                  <year>2012</year>
                  <volume>110</volume>
                  <fpage>89</fpage>
                  <lpage>98</lpage>
                  <pub-id pub-id-type="doi">10.1007/s11060-012-0938-9</pub-id>
                  <?supplied-pmid 22821383?>
                  <pub-id pub-id-type="pmid">22821383</pub-id>
                </element-citation>
              </ref>
              <ref id="CR65">
                <label>65.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Dias-Santagata</surname>
                      <given-names>D</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine</article-title>
                  <source>EMBO Mol. Med.</source>
                  <year>2010</year>
                  <volume>2</volume>
                  <fpage>146</fpage>
                  <lpage>158</lpage>
                  <pub-id pub-id-type="doi">10.1002/emmm.201000070</pub-id>
                  <?supplied-pmid 20432502?>
                  <pub-id pub-id-type="pmid">20432502</pub-id>
                </element-citation>
              </ref>
              <ref id="CR66">
                <label>66.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cairncross</surname>
                      <given-names>JG</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas</article-title>
                  <source>J. Natl Cancer Inst.</source>
                  <year>1998</year>
                  <volume>90</volume>
                  <fpage>1473</fpage>
                  <lpage>1479</lpage>
                  <pub-id pub-id-type="doi">10.1093/jnci/90.19.1473</pub-id>
                  <?supplied-pmid 9776413?>
                  <pub-id pub-id-type="pmid">9776413</pub-id>
                </element-citation>
              </ref>
              <ref id="CR67">
                <label>67.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hegi</surname>
                      <given-names>ME</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>MGMT gene silencing and benefit from temozolomide in glioblastoma</article-title>
                  <source>New Engl. J. Med.</source>
                  <year>2005</year>
                  <volume>352</volume>
                  <fpage>997</fpage>
                  <lpage>1003</lpage>
                  <pub-id pub-id-type="doi">10.1056/NEJMoa043331</pub-id>
                  <?supplied-pmid 15758010?>
                  <pub-id pub-id-type="pmid">15758010</pub-id>
                </element-citation>
              </ref>
              <ref id="CR68">
                <label>68.</label>
                <mixed-citation publication-type="other">Bogner, W. et al. in <italic>Proceedings of the 23rd Annual Scientific Meeting of the ISMRM, Toronto, Canada, 30 May–5 Jun, 2015</italic>.</mixed-citation>
              </ref>
              <ref id="CR69">
                <label>69.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ogg</surname>
                      <given-names>RJ</given-names>
                    </name>
                    <name>
                      <surname>Kingsley</surname>
                      <given-names>PB</given-names>
                    </name>
                    <name>
                      <surname>Taylor</surname>
                      <given-names>JS</given-names>
                    </name>
                  </person-group>
                  <article-title>Wet, a T-1-Insensitive and B-1-Insensitive Water-Suppression Method for in-Vivo Localized H-1-Nmr Spectroscopy</article-title>
                  <source>J. Magn. Reson. B.</source>
                  <year>1994</year>
                  <volume>104</volume>
                  <fpage>1</fpage>
                  <lpage>10</lpage>
                  <pub-id pub-id-type="doi">10.1006/jmrb.1994.1048</pub-id>
                  <?supplied-pmid 8025810?>
                  <pub-id pub-id-type="pmid">8025810</pub-id>
                </element-citation>
              </ref>
              <ref id="CR70">
                <label>70.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>van der Kouwe</surname>
                      <given-names>AJW</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>On-line automatic slice positioning for brain MR imaging</article-title>
                  <source>Neuroimage</source>
                  <year>2005</year>
                  <volume>27</volume>
                  <fpage>222</fpage>
                  <lpage>230</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.neuroimage.2005.03.035</pub-id>
                  <?supplied-pmid 15886023?>
                  <pub-id pub-id-type="pmid">15886023</pub-id>
                </element-citation>
              </ref>
              <ref id="CR71">
                <label>71.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Provencher</surname>
                      <given-names>SW</given-names>
                    </name>
                  </person-group>
                  <article-title>Estimation of metabolite concentrations from localized in-vivo proton NMR-spectra</article-title>
                  <source>Magn. Reson. Med.</source>
                  <year>1993</year>
                  <volume>30</volume>
                  <fpage>672</fpage>
                  <lpage>679</lpage>
                  <pub-id pub-id-type="doi">10.1002/mrm.1910300604</pub-id>
                  <?supplied-pmid 8139448?>
                  <pub-id pub-id-type="pmid">8139448</pub-id>
                </element-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
